The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Learn more about AbbVie’s response to COVID-19

IDENTIFYING PATIENTS WITH PsA

WHO MAY BENEFIT FROM
TREATMENT WITH SKYRIZI

WATCH A PEER-LED DISCUSSION ABOUT SKYRIZI IN bio-naïve PATIENTS

SKYRIZI IN BIO-NAÏVE PATIENTS

To better inform decisions around PsA treatment selection in clinical practice, it’s important to identify where in their disease progression a patient may be and what their treatment goals are.

Watch Dr. Schwartzman and Dr. Khattri identify how a bio-naïve patient may present in clinical practice and give an overview of the demographics of the patient population in the KEEPsAKE 1 PsA trial.

MEET THE KEY OPINION LEADERS

SERGIO SCHWARTZMAN, MD

Dr. Schwartzman completed an internship and residency in internal medicine at Long Island Jewish Medical Center in New Hyde Park, New York, and fellowships in the Division of Rheumatic Diseases at New York Hospital and the Hospital for Special Surgery.

Dr. Schwartzman is a member of the American College of Rheumatology, the Spondyloarthritis Research & Treatment Network, the American Uveitis Society, and the Group for Research and Assessment of Psoriasis. He is the Franchellie M. Cadwell Emeritus chair at the Hospital for Special Surgery, Associate Attending Physician at the New York Presbyterian Hospital, and Associate Professor Medicine at Weill Cornell Medical Center.

He is currently in private practice in New York City and has over 34 years of experience and focus in the areas of PsA, RA, AS, autoimmune eye disease, and IBD-associated arthritis.

Dr. Sergio Schwartzman.
Dr. Saakshi Khattri.

SAAKSHI KHATTRI, MD

Dr. Saakshi Khattri is a board-certified rheumatologist, dermatologist, and internist and one of only a handful of triple-board-certified physicians across the United States.

After completing her MBBS from Delhi University, Dr. Khattri moved to New York to complete her internal medicine residency followed by a fellowship in rheumatology at the Albert Einstein College of Medicine in New York. She completed a 2-year research fellowship at Rockefeller University where she conducted research and ran clinical trials in atopic dermatitis and psoriasis under the mentorship of Dr. Emma Guttman and Dr. James Krueger.

Dr. Khattri then successfully completed a residency in dermatology at the Icahn School of Medicine at Mount Sinai.


PASI 90 & PASI 100 RESPONSES

In patients with PsA2-5

Patient Icon.

WELL-STUDIED SAFETY PROFILE

Across indications1

Safety Icon.